Dr. Reddy’s Laboratories will meet on July 22 to declare its Q1 FY27 financial results. The company will also hold its annual general meeting on July 23 to seek approval for an Rs 8 per share final dividend for FY26. Investors are watching these results to assess core profitability after a major accounting adjustment impacted recent quarterly earnings.
What Happened
Dr. Reddy’s Laboratories Ltd. is set to announce its financial results for the first quarter of fiscal year 2027 on July 22, 2026. The company’s board of directors will meet to review the standalone and consolidated financial statements for the period ending June 30, 2026.
Following the results, the company will hold its 42nd annual general meeting on July 23, 2026. A primary agenda item for shareholders will be the approval of a final dividend of Rs 8 per equity share for the financial year ended March 31, 2026. The company has set July 10 as the record date for determining eligible shareholders, with payments expected to be distributed by July 30.
The Profitability Context
These upcoming results follow a difficult fourth quarter in the previous fiscal year, where the company reported an 86% year-on-year decline in consolidated net profit. The profit fell to Rs 221 crore, compared to Rs 1,593 crore in the same period a year earlier. This drop was largely driven by a Rs 4,530 crore one-time accounting adjustment related to Lenalidomide, a specific drug in its portfolio.
Investors are looking past this significant one-time charge to see how the company’s normal business operations are performing. In the previous quarter, consolidated revenue also declined 12% to Rs 7,546 crore, and the operating profit margin contracted to 13% from 29% in the prior year. The upcoming Q1 figures will provide clarity on whether the core business margins are stabilizing without these heavy accounting adjustments.
Market and Share Price
Dr. Reddy’s shares recently closed at Rs 1,290.70. The stock has been trading within a range of Rs 1,271.20 to Rs 1,306.00 in the most recent session. Over the past 52 weeks, the share price has fluctuated between a low of Rs 1,148.40 and a high of Rs 1,375.90. The company currently holds a market capitalization of approximately Rs 1.10 lakh crore, with a price-to-earnings (P/E) ratio of 19.63.
What Investors Should Track
For investors, the key area of focus for the upcoming results will be the operating margins. With the major one-time charge behind them, the market will assess if the company can maintain profitability in its key markets, particularly in the competitive generic drug space. Investors may also monitor management commentary regarding demand for their product portfolio and any updates on new product launches, which are vital for revenue growth. The ability to manage costs effectively while maintaining market share in the US and other international markets will remain a critical monitorable for the business.